Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Single-Cell Sequencing of Diffuse Midline Glioma Reveals That CTHRC1 Promotes Tumor Malignant Progression via the Wnt/β-Catenin/MMP2 Signaling Pathway.

Created on 28 Oct 2026

Authors

Yong Gao, Ziyuan Yu, Yinan Xie, Lei Chen, Linyong Shi, Rongzhang Zhu, Yuntao Lu

Published in

IUBMB life. Volume 78. Issue 10.

Abstract

Despite the continuous advancement of neurosurgical techniques and the accelerated pace of drug development, the prognosis of diffuse midline glioma (DMG) remains unsatisfactory. Reports on the cellular atlas and biological characteristics of DMG remain relatively scarce. With the rapid development of biotechnology, especially single-cell transcriptome technology, people's understanding of the tumor microenvironment (TME) of DMG can be effectively enhanced. Here, we performed an integrated analysis of single-cell transcriptome profiles from 3 DMG samples collected from our center to investigate the characteristics of intratumoral heterogeneity and the TME. As a core component of DMG tumor cells, oligodendrocyte progenitor cells (OPCs) are predominantly localized in the cellular tumor (CT) region, whereas OPCs in the leading edge (LE) and microvascular proliferation (MVP) regions contribute to immune suppression. The pseudotime trajectory of monocyte-derived macrophages (MDMs) demonstrates that they infiltrate the tumor tissues via the microvascular proliferation (MVP) and leading edge (LE) regions, and then migrate toward the tumor core (CT) or pseudo-palisading cells around necrosis (PAN) regions, which is correlated with tumor immune suppression. In addition, CTHRC1 can promote the malignant progression of DMG via the Wnt/β-catenin/MMP2 signaling pathway. Together, our work provides an in-depth understanding of the microenvironment of DMG, thereby laying a framework for uncovering targeted therapeutic strategies for DMG.

PMID:
42947570
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 30
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement